Meeting
2021 ASCO Annual Meeting
Age affects the efficacy of immune checkpoint inhibitors in patients with advanced cancer.
Authors
Yongjie Wang
The Affiliated Hospital of Qingdao University, Qingdao, China
Yongjie Wang , Ronghua Yang , Dong Wang , Donghua Zhao , Peng Li , Mengjun Li , Yingxue Qi , Ningning Luo , Yaqing Wu , Qin Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2638)
DOI
10.1200/JCO.2021.39.15_suppl.2638
Abstract #
2638
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.
First Author: Honghai Dai
Poster
2019 ASCO Annual Meeting
Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.
First Author: Vaia Florou
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial.
First Author: Xiaoting Ma
Poster
2023 ASCO Annual Meeting
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
First Author: Jarushka Naidoo